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ABSTRACT 
The t(4;11)(q21;q23) chromosomal translocation results in the KMT2A/AFF1 
fusion gene, which encodes the mixed-lineage leukemia (MLL)-AF4 
oncogenic chimera, a hallmark of an aggressive form of acute lymphoblastic 
leukemia (ALL). In t(4;11) ALL, MLL-AF4 recruits the endogenous co-
activator AF4 and aberrantly triggers transcription of MLL target genes, 
including HOXA9 and MEIS1, thereby driving transformation of 
hematopoietic progenitors. We previously demonstrated that the scaffold 
protein 14-3-3θ is a direct interactor of AF4 and promotes AF4 binding to the 
HOXA9 promoter. Notably, 14-3-3θ is a target of MiR-27a, which acts as 
tumor suppressor in various human leukemias; moreover, expression levels 
of MiR-27a correlate with relapse free survival in childhood ALL. This PhD 
thesis aims to assess the potential role of MiR-27a in t(4;11) ALL 
pathogenesis. In different leukemia cell lines, we found an inverse correlation 
between levels of MiR-27a and 14-3-3θ, which was particularly relevant in 
t(4;11) cell lines. In t(4;11) leukemia cells, transient transfection of MiR-27a 
led to a decrease in 14-3-3θ protein amount and HOXA9, HOXA7 and MEIS1 
transcription. Interestingly, our bioinformatic analysis predicted that AFF1-
3’UTR, which is shared with KMT2A/AFF1, contains a putative MiR-27a 
seed sequence. Consistently, MiR-27a overexpression strongly reduced AF4 
and MLL-AF4 protein levels, as well as protein level of RUNX1, a known 
target of MiR-27a with a key role in t(4;11) leukemia context. We therefore 
cloned AFF1-3’-UTR in an opportune plasmid vector and performed a 
luciferase reporter assay. The decreased luciferase activity we measured after 
co-transfection of MiR-27a and the recombinant plasmid proved that AFF1-
3’UTR is a direct target of MiR-27a. Accordingly, transfection of anti-MiR-
27a enhanced the expression of AF4 protein, in RS4;11 cells. Moreover, 
ChIP experiments gave direct proof that MiR-27a overexpression impaired 
MLL-AF4 binding to HOXA9 promoter. Consistently, MiR-27a 
overexpression decreased viability, proliferation and clonogenicity of t(4;11) 
cells, whereas enhanced their apoptotic rate. Lastly, we found that relative 
expression of MiR-27a was significantly lower in 9 patients affected by 
severe t(4;11) ALL compared with 9 patients affected by t(12;21) leukemia, 
which has a benign prognosis. Similarly to the t(4;11) cell lines, in our ALL 
patients we found an inverse relationship between MiR-27a and 14-3-3θ 
transcript levels. Overall, we demonstrate that MiR-27a has a pivotal role in 
t(4;11) ALL molecular pathogenesis and therefore it is a promising novel 
target for the therapy of this aggressive form of leukemia.
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1. INTRODUCTION 
1.1 Leukemia 
 
Leukemia is a progressive and malignant neoplasm that usually starts in bone 
marrow and is caused by the rapid and uncontrolled proliferation of abnormal 
white blood cells. This heterogeneous group of diseases is characterized by 
infiltration of blood, bone marrow and other tissues by neoplastic cells of 
hematopoietic origin (Fig.1); indeed, the replacement of marrow space by 
leukemic cells may suppress the normal hematopoiesis thus resulting in 
anemia, thrombocytopenia and granulocytopenia. Other clinical 
manifestations are due to organ infiltration that causes hepatomegaly, 
splenomegaly and enlargement of lymph nodes. 
The molecular alteration that causes the malignant transformation usually 
occurs in a pluripotent stem cell, although it sometimes involves committed 
stem cells with less self-renewal capacity. Therefore, leukemia can be either 
acute or chronic, depending on the differentiation degree of the transformed 
cell. Acute leukemia is characterized by immature and poorly differentiated 
cells called “blasts”, whereas the chronic form presents more mature cells 
and progresses more slowly than the acute ones. Leukemia is also classified 
in lymphocytic and myelocytic, depending on the origin of the malignant 
clone. Thus, there are four broad classifications of leukemia:  
• Acute lymphocytic leukemia (ALL) 
• Acute myelocytic leukemia (AML) 
• Chronic lymphocytic leukemia (CLL) 
• Chronic myelocytic leukemia (CML) 
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Figure 1. Hematopoiesis includes proliferation and differentiation processes that produce 
all the mature cellular elements of blood. An arrest in the differentiation process leads to 
leukemic transformation (Riether et al, 2015). 
 
Each class is further sub-divided into subtypes according to two staging 
systems. The French-American-British (FAB) classification system is based 
on morphology to define specific immunotypes, whereas the World Health 
Organization (WHO) classification focuses on chromosome translocations 
and evidence of dysplasia. The diagnostic workflow is based on complete 
blood count, peripheral blood smear, bone marrow aspiration and biopsy. 
Leukocytosis and presence of immature blood-forming cells in bone marrow 
aspiration contribute to the diagnosis. To confirm diagnosis, flow cytometry 
is carried out to define the immunophenotype of leukemic cells. In addition, 
cytogenetic and molecular biology analyses are performed, in order to 
classify the disease, to define the best therapeutic strategy and to monitor 
minimal residual disease. 
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1.2 Acute lymphoblastic leukemia  
 
Acute lymphoblastic leukemia (ALL) is caused by malignant transformation 
and proliferation of lymphoid progenitor cells in bone marrow, blood and 
extramedullary sites (Fig.2). In 80% of cases, the disease affects children, 
whereas in adults is rare and characterized by a worse prognosis. The 
incidence of ALL follows a bimodal distribution with the first peak occurring 
in childhood and the second one around the age of 50 years. 
 
 
Figure 2. Bone marrow aspirate from a patient diagnosed with B-ALL. Nucleated marrow 
cells are mostly leukemic blasts of similar appearance representing undifferentiated round-
shaped clones with evident nucleoli and condensed chromatin 
(http://www.pedsoncologyeducation.com/ALLBMbiopsy.asp). 
 
In most cases, ALL appears as a de novo malignancy in healthy patients, but 
some predisposing factors exist, such as environmental factors (exposure to 
ionizing radiation, pesticides, some solvents, viruses) and genetic syndrome 
(Down syndrome, Fanconi anemia) (Terwilliger et al, 2017). Malignant 
transformation and uncontrolled proliferation of an aberrantly differentiated, 
long-lived lymphoid progenitor cells results in a high circulating number of 
blasts, replacement of normal marrow by malignant cells and potential 
leukemic infiltration of the central nervous system (CNS) and abdominal 
organs. Symptoms include fatigue, pallor, infection, bone pain and easy 
bruising and bleeding. According to the FAB classification system, ALL is 
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divided into three subtypes (L1, L2, L3) based on morphological features like 
cell size, cytoplasm, nucleoli, vacuolation and basophilia. The WHO 
classification, revised in 2008, takes into account both morphology and 
genetic alterations and identifies the B- and T-ALL types. B-ALL is further 
divided into two subtypes: B-ALL with recurrent genetic abnormalities and 
B-ALL not otherwise specified. B-ALL with recurrent genetic abnormalities 
is delineated on the basis of the specific chromosomal rearrangement that is 
present in the transformed cell. In fact, most of childhood ALL cases harbor 
gross chromosomal aberrations. In B-ALL, these alterations include high 
hyperdiploidy with non-random gain of at least five chromosomes (including 
X, 4, 6, 10, 14, 17, 18, and 21), hypodiploidy with fewer than 44 
chromosomes and recurring translocations (Fig.3).  
 
 
Figure 3. Spectrum of recurring chromosomal rearrangements in childhood ALL (Mignon et 
al, 2012). 
 
The most common rearrangements in ALL include t(12;21)(p13;q22), which 
encodes the ETV6-RUNX1 (TEL-AML1) chimera; t(1;19) (q23;p13), which 
produces the fusion protein TCF3-PBX1 (E2A-PBX1); t(9;22)(q34;q11), 
which arises Philadelphia chromosome and the oncogenic BCR-ABL1 
chimera; rearrangements of the 11q23 chromosome region, which involve the 
MLL gene and a variety of partner genes. In most cases, the primary genetic 
alteration is not sufficient to cause leukemia, but can promote, in a sub-set of 
cancer cells, the acquisition of additional genomic changes that allow to the 
cell to gain further grown advantages. In fact, more than 50 regions of 
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recurring DNA copy number alteration (CNA) have been identified in ALL 
cells. Many of them involve genes that encode regulators of lymphoid 
development and of cell cycle, tumor suppressors and lymphoid signaling 
molecules. Very interestingly, the MLL-rearranged (MLL-r) ALL, which is 
typically aggressive and arises early in life, harbors < 1 additional genetic 
alteration per case (Inaba et al, 2013). 
The current treatment of ALL comprises induction combination 
chemotherapy to achieve remission; intrathecal chemotherapy for CNS 
prophylaxis and/or cerebral irradiation for intracerebral leukemic infiltration; 
consolidation chemotherapy with or without stem cells transplantation; and 
maintenance chemotherapy for up to 3 years to avoid relapse. Drug dosage 
and schedule of administration in combination chemotherapy have been 
optimized on the basis of leukemic-cell biological features, response to 
therapy, patient’s pharmacodynamic and pharmacogenomic findings, thus 
resulting in the current high survival rate. A very recent therapeutic strategy 
is represented by cancer immunotherapy, which uses the body’s immune 
system to seek out and destroy malignant cells, using tumor-specific antigen 
recognition. The principle advantages of this therapy is the ability of the T 
cells to expand and go after target cells, with the potential for surveillance 
through T-cell memory (Singh et al, 2016). Chimeric antigen receptor (CAR) 
T-cell therapy seems to be a successful therapeutic option for patients with 
relapsed or refractory ALL (Callahan et al, 2017). 
 
 
1.3 Abnormalities of the MLL gene in ALL 
 
The mixed-lineage-leukemia (MLL) gene rearrangements are present in 80% 
of infant B-ALL cases and 10% of total childhood B-ALL (Woo et al, 2014). 
In some cases, MLL is target of insertion, deletion, partial tandem repeats; 
however, balanced chromosomal translocation is the most common genomic 
rearrangement involving MLL gene (Meyer et al, 2018). Such balanced 
translocations fuse in frame the genomic sequences encoding the N-terminus 
domains of the histone methyltransferase MLL with the genomic sequences 
encoding the C-terminus domains of a fusion partner gene. To date, about 80 
direct (MLL-X) and 120 reciprocal (X-MLL) MLL fusion genes have been 
identified in acute leukemia patients (Marschalek et al, 2016). The chimeric 
proteins encoded by these fusion genes cause the self-renewal of 
hematopoietic progenitors due to aberrant expression of genes normally 
controlled by MLL (Slany, 2009; Yokoyama et al, 2015). 
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The most common gene rearrangements are: 
• t(4;11)(q21;q23) encoding MLL-AF4; 
• t(9;11)(p22;q23) encoding MLL-AF9; 
• t(11;19)(q23;p13.3) encoding MLL-ENL; 
• t(10;11)(p13-14;q14-21) encoding MLL-AF10. 
About 50% of MLL-r ALL displays the t(4;11)(q21;q23) translocation and is 
associated with very poor survival (Woo et al, 2014). 
Despite this wide genetic variety, most cases of MLL-r ALL have a clinical 
entity and gene expression signatures that do not depend on the fusion partner 
involved in leukemogenesis. One of the reasons is that MLL fusion proteins 
(MLL-FP) share a common structure with the respective partners invariably 
fused in frame to the MLL’s N-terminus. Moreover, most of fusion partners 
are nuclear proteins, whereas cytoplasmatic ones are present in rarely 
occurring MLL-FP. It is known that MLL-FPs function as a novel type of 
general transcription factors, which are able to indiscriminately activate many 
different promoters (Slany, 2009). Notably, some of the known partner 
proteins are involved into the regulation of transcriptional initiation and 
elongation, as they directly bind to either RNA polymerase II (Pol II) or a 
part of a multiprotein super elongation complex (SEC) that interacts with Pol 
II. However, the pathological role of many fusion partner genes has not been 
well elucidated yet (Marschalek, 2016). 
 
 
1.3.1 Structure and function of MLL 
 
The normal MLL gene at the 11q23 locus, also known as 
MLL1/HRX/HTRX1/ALL1/KMT2A, encodes an approximately 500-kDa 
nuclear protein with multiple functional domains and binding partners, which 
is expressed in a wide variety of normal human tissues (Winters et al, 2017). 
Human MLL protein is both structurally and functionally homologous to the 
Drosophila melanogaster protein trithorax (trx), which is an epigenetic 
regulator of developmental genes. The common downstream targets of MLL 
and trx are the homeobox (HOX) genes, which control segment specificity 
and cell fate in the developing embryo (Krumlauf, 1994). The N-terminal of 
MLL contains a binding domain for Menin, a protein that links MLL and the 
chromatin-binding protein lens epithelium-derived growth factor (LEDGF). 
LEDGF, thanks to its PWWP domain, binds to dimethylated lysine 4 on 
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histone 3 (H3K36me2) a signature placed by the histone methyltransferase 
ASH1L. The MLL N-terminus also contains AT-hook motifs, which mediate 
the binding to the minor groove of DNA helix, speckled nuclear localization 
domain 1 and 2 (SNL-1 and SNL-2), and two repression domains, RD1 and 
RD2. RD1 contains a CXXC domain, a region with homology to DNA 
methyltransferase 1 (DNMT1) that binds to non-methylated CpG DNA. RD2 
is able to interact with HDAC1 e HDAC2. All of these domains are typically 
conserved in chimeric MLL fusion proteins (Winters et al, 2017). The 
PWWP and CXXC motifs constitute minimum targeting modules (MTM) 
that allow the MLL-FPs to aberrantly recognize the target chromatin. 
Moreover, some evidence indicates that the association between CXXC 
domain and non-methylated CpGs drives the target recognition, whereas the 
association between LEDGF and H3K36me2 reinforces the interaction with 
the target chromatin (Yokoyama, 2017). The middle portion of MLL contains 
four plant homeodomain (PHD) fingers, which mediate protein–protein 
interactions, and a bromodomain (BD). The PHD3 subdomain is able to read 
H3K4me2/3 chromatin signatures and is stabilized via a protein helix to BD 
domain. In particular, when PHD3 interacts with CYP33/PPIE (a prolyl 
isomerase) a conformational change occurs; PHD3 loses its reading function 
and it is no longer able to interact with BD domain. Therefore, PHD3 domain 
is able to recruit and bind to the BMI1/HPC2/HDAC1-2/CtBP complex. 
MLL binding to Polycomb-group proteins converts MLL into a 
transcriptional repressor, which is important for negative regulation of certain 
MLL target genes. Chromosomal rearrangements in MLL-r leukemias destroy 
the above described intrinsic control mechanism of the MLL protein 
(Marschalek, 2016). Indeed, MLL-FPs lose the C-terminal portion of MLL, 
which contains a transcriptional activation domain and a SET domain. The 
SET domain is homologous to that of Drosophila trx and it is able to catalyze 
mono-, di-, and tri-methylation of lysine 4 on histone 3 (H3K4) in vitro. 
These marks are usually present at transcriptionally active chromatin regions 
(Santos-Rosa et al, 2002). Other essential proteins that make up the core of 
the MLL complex include RbBP5, Ash2L and WDR5 (Vedadi et al, 2017). 
This such formed complex is able to bind a variety of H3K4 
methyltransferases with SET domains, including MLL, which is thus able to 
directly bind to HOX gene promoters, inducing their specific regulation 
(Milne et al, 2002). 
After its translation, wild-type MLL is processed by the Taspase1 enzyme. 
Proteolytic cleavage gives rise to a 320 kDa N-terminal fragment (MLL
N
) 
and a 180 kDa C-terminal fragment (MLL
C
). MLL
N
 and MLL
C
 normally 
assemble each other via FYRN and FYRC domains, which belong 
respectively to MLL
N 
and MLL
C 
fragments (Fig.4). It has been observed that 
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the translocation breakpoint distribution is somehow linked to the age of 
patients. In particular, infant ALL patients (early disease onset) tend to have 
the breakpoint within the MLL intron 11 (Marschalek, 2016). It has been 
demonstrated that breakpoints within the MLL intron 11 are associated with a 
worse clinical outcome (Emerciano et al, 2013). 
 
 
Figure 4. Representation of the full-length MLL protein. Exons (1-37) and the major break 
cluster region (BRX) are shown above the protein structure. All known binding proteins and 
the domains with the associated function are depicted (Marschalek, 2016). 
 
  
1.3.2 MLL and the HOX genes 
 
HOX proteins are a deeply conserved group of transcription factors originally 
recognized for their role in determining segmental identity along the antero-
posterior (AP) axis in Drosophila. The role of Hox genes in establishing AP 
axis identity is conserved in vertebrates. The spatial and temporal expression 
patterns of Hox genes along the AP axis of flies depend on their position on 
the chromosome (Pascual-Anaya, 2013). The vertebrate counterparts are 
usually grouped in four clusters. In human, the four HOX gene clusters (A-D) 
are located on four different chromosomes, HOXA (7p15), HOXB (17q21), 
HOXC (12q13) and HOXD (2q31) (Alharbi et al, 2013) (Fig.5). 
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Figure 5. (A) The genomic architecture of HOX genes and (B) schematic representation of 
gene expression in embryonic development (Decker et al, 2014). 
 
Mammalian HOX genes are constituted by two exons and a single intron, 
which varies from less than 200 bases to several kilobases. HOX protein 
structure is characterized by an acidic tail at the C-terminus and a pentamer 
upstream of the homeodomain that binds the three amino acids loop 
extension (TALE) proteins, which act as cofactors. Indeed, PBX and MEIS 
are the main co-factors of HOX proteins. Of note, the formation of HOX-
PBX-MEIS heterotrimeric complexes is essential for the execution of HOX-
dependent developmental programs (Thorsteinsdottir et al, 2001). The 
homeodomain is a highly conserved DNA-binding region of 60 amino acids 
(Lappin et al, 2006). 
In human, HOX genes are involved in the regulation of hematopoiesis, from 
post-embryonic stage and throughout adult life (Slany et al, 2005). Multiple 
HOX genes of clusters A, B and C are expressed in hematopoietic stem cells. 
Normally, when down-regulation of many HOX genes occurs, the progenitor 
cells differentiate (Lappin et al, 2006). Some experimental evidence 
demonstrates that HOX genes, and in particular HOXA9, is overexpressed in 
more than 50% of AML and in a subset of B and T ALL, with particular 
relevance in MLL-r leukemia (Collins et al, 2016). Chromatin 
immunoprecipitation experiments showed that MLL-FPs effectively bind to 
the DNA locus of the HOXA9 gene (Milne et al, 2005). Moreover, HOXA9 
knockdown in MLL-r leukemia cell lines induces apoptosis and reduces 
colony forming potential of the cells (Fig.6).  
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Figure 6. Regulation of HOXA9 expression in normal and malignant hematopoiesis. (A) 
During normal hematopoiesis, HOXA9 is expressed most highly in early progenitor cells and 
its expression is subsequently down regulated as cells become terminally differentiated. (B) 
In normal hematopoiesis, HOXA9 expression is regulated by the MLL histone 
methytransferase. (C) In approximately 50% of acute leukemias, HOXA9 is highly expressed 
as the result of the MLL1-fusions production (Collins et al, 2016). 
 
 
When MLL-r cells are subjected to HOXA9 knockdown and then transplanted 
into mice, the mice leukemic phenotype is attenuated (Orlovsky et al, 2011). 
HOXA9 is required for the maintenance of leukemic state (Faber et al, 2009) 
and elevated levels of HOXA9 lead to a long latency form of leukemia 
(Kroon et al, 1998). MEIS1 is another target gene of MLL-FPs (Armstrong et 
al, 2002). Even though, high levels of MEIS1 are not sufficient to induce 
leukemia, the co-expression of HOXA9 and MEIS proteins reduces the 
latency of HOXA9-induced leukemia. These data suggest a key role of these 
two proteins in the initiation and maintenance of leukemic state (Roth et al, 
2009). Recently, it has been discovered that murine Pbx3, another TALE 
family component, plays an important role in leukemia associated to Hoxa9 
deregulation, in mice. Indeed, Pbx3 takes part to Hoxa9 and Meis1 
interaction; it protects Meis1 from ubiquitination and proteasome-mediated 
degradation. Since Meis1 half-life is extended and the interaction with Hoxa9 
is increased, their gene regulatory activity is enhanced (Garcia-Cuellar et al, 
2015). HOXA9 and MEIS1 overexpression are inversely correlated with 
relapse and overall survival, thus these genes could become useful predictive 
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markers of the clinical development of acute leukemias (Adamaki et al, 
2015). 
 
 
1.4 The t(4;11)(q21;q23) ALL 
 
Rearrangements of the MLL gene are common genetic events in 
hematological malignancies. They are present in around 10% of ALL and 5% 
of AML. About 50% of patients diagnosed with pro-B ALL aged 6 months or 
less harbors the t(4;11) chromosomal rearrangement. Frequency of the t(4;11) 
ALL decreases in older infants (10–20%) and drops to just 2% in children. In 
adult B-ALL, it accounts for about 10% of cases (Malouf et al, 2018). 
Leukemia blasts has a pro-B/mixed leukemia phenotype, lacking in CD10 
and co-expressing B lymphoid markers (CD19, CD22, CD79a, Tdt) and 
myeloid markers (CD15, CD65). An interesting feature of t(4;11) infant 
patients is the expression of MLL-AF4 chimera in a subset of bone marrow 
mesenchymal stem cells (MSC). This was not observed in other types of B-
ALL and seems to be unique to this group of patients. This finding suggests 
the initial translocation occurs in a precursor that is common for 
hematopoietic and stromal compartment (Malouf et al, 2018).The genetic 
landscape of t(4;11) infant patients shows that this highly aggressive 
leukemia contains remarkably few somatic mutations, having one of the 
lowest somatic coding mutation rates observed in a human cancer to date 
(Andersson et al, 2015). Thus, it is very likely that the t(4;11)(q21;q23) is the 
first driving mutation (Fig.7A). Notably, some epidemiological and genetic 
studies showed that exposure to the anti-cancer drug etoposide increases the 
susceptibility to breakage of the 11q23 locus. Etoposide inhibits 
topoisomerase II and, therefore, causes breaks in both DNA strands (Sanjuan-
Pla et al, 2015). 
The t(4;11)(q21;q23) balanced translocation fuses in frame the first 8-11 
exons of MLL, at 11q23, with the last 13-20 exons of AFF1, at 4q21, 
producing a fusion transcript that encodes the oncogenic MLL-AF4 chimera 
(240 kDa). This oncoprotein retains MT, AT hook and SNL domains of MLL 
at the N-terminal, whereas the C-terminal is the transactivation domain of 
AF4, the AFF1 gene product (Lavau et al, 1997) (Fig.7B). The proposed 
mechanism by which MLL-AF4 chimera could provoke leukemia is based on 
the aberrant transcriptional activation of the MLL target genes driven by the 
fusion partner portion (Slany et al, 2009). 
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Figure 7. (A) On the left, G-banded karyotype showing the balanced t(4;11)(q21;q23) 
translocation [arrows]; in the right panel, dual color FISH on a metaphase with 
t(4;11)(q21;q23)(http://atlasgeneticsoncology.org). (B) Schematic representation of the 
MLL-AF4 oncoprotein functional domains. 
 
 
1.4.1 The AFF1 gene and the AF4 protein  
 
The AFF1 gene at 4q21 locus is 134050 bp long and consists of 23 exons. 
The first 4 exons are alternatively spliced in the mature transcript. The 
mRNA is 9390 bp long, with an open reading frame of 3633 bp. It produces 
the AF4 protein of 1210 aminoacids with a molecular weight of 140 kDa. It 
is a ubiquitous, mainly nuclear, protein and its expression is particularly high 
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in lymphoid organs, placenta, CNS and kidney (Frestedt et al, 1996). AFF1 
gene is critical for early events of normal lymphopoiesis in mice, such as 
precursor proliferation or recruitment. Indeed AFF1-knockout mice showed a 
reduced number of B and T lymphocytes in hematopoietic organs as bone 
marrow, thymus and spleen (Isnard et al, 2000). AF4, AF5q31, LAF4 and 
FMR belong to the ALF family protein. The ALF family members share the 
highly conserved N-terminal homology domain (NHD), C-terminal 
homology domain and the ALF domain, which is characterized by a serine-
proline rich region (Fig.8). Each member of this family features a 
transactivation domain except for FMR2, which is the only one not found as 
MLL fusion partner. AF4, together with the other members of ALF family, 
associate to ENL and to p-TEFb in order to form SEC/AEP complex. ENL is 
a histone acetylation reader and contributes to promote transcription 
elongation (Zhou et al, 2018). P-TEFb, which is formed by cyclin-dependent 
kinase 9 (CDK9) and cyclin T1, promotes the transcription elongation phase 
by phosphorylating the Pol II C-terminal domain (CTD). AF4 stimulates 
kinase activity of p-TEFb and associates with DOT1L, a methyltranferase 
that metylates histone H3 at lysine 79. This epigenetic modification remodels 
and marks transcriptionally active chromatin (Yokoyama et al, 2010). 
 
 
Figure 8. Schematic representation of AF4 functional domain. 
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1.4.2 AF4 interactome 
 
The AF4 function has been unclear for a long time. Many efforts have been 
done to unravel its physiologic role in cells. Some clues derive from the 
discovery and the study of its direct and indirect interactors. The AF4 
interactome comprises mainly nuclear proteins, but also cytosolic ones. To 
date, AF4 is classified as a transcriptional activator. Immunoprecipitation 
experiments revealed that AF4 interacts with ENL and p-TEFb and forms the 
SEC/AEP (AF4 family/ENL family/p-TEFb complex) complex, which is 
physiologically recruited by MLL on some of its target genes (Yokoyama et 
al, 2010). P-TEFb phosphorylates C-terminal domain (CTD) of Pol II and 
promotes transcriptional elongation. In particular, AF4 interacts with CDK9 
and stimulates its kinase activity. On the other hand, p-TEFb is able to 
phosphorylate N-terminus of AF4, thereby decreasing its transactivation 
activity. The MLL-AF4 chimera does not undergo to this negative regulation 
because the N-terminal domain of AF4 is lost (Esposito et al, 2011; 
Yokoyama et al, 2010). AF4 exerts its transcriptional activator function as a 
homodimer or heterodimer with AF5q31, another ALF homologue. The AF4 
C-terminal region, which is retained in MLL-AF4 chimera, is responsible for 
dimerization. Therefore, MLL-AF4 and AF4/AF5q31 can form a dimeric 
complex in leukemic cells. AF9, which is also a fusion partner of MLL in 
leukemias, is a known interactor of AF4. AF9 associates with ENL and 
DOT1L, which form a complex involved in transcriptional elongation and 
chromatin remodeling (Yokoyama et al, 2010).  
AF4 interactome contains proteins, such as ELL and EAF1, that are involved 
in transcription. ELL is a positive transcription factor that works by 
suppressing Pol II pauses along DNA filament. Interestingly, also ELL is a 
fusion partner of MLL in several ALL. EAF1 is a strong positive regulator of 
the ELL elongation activity; it binds the ELL C-terminal domain and 
activates transcription. ELL and EAF1, together with AF4, p-TEFb, ENL and 
AF5 q31, belong to super elongation complex (SEC). SEC has the major role 
in transcription elongation and could be constitutively recruited by MLL-AF4 
chimera on MLL target genes (Yokoyama et al, 2010). Other information 
about AF4 interactome comes from a wide functional proteomic study, which 
identified 51 proteins that directly or indirectly interact with AF4 (Esposito et 
al, 2011) (Fig.9). 
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Figure 9. Schematic representation of various AF4 partner and their interaction network. 
Proteins that are part of the same multiprotein complex or to protein family are highlighted 
(Esposito et al, 2011). 
 
About 60% of these proteins are involved in Pol II-mediated transcription 
regulation. Among these, there are the two major subunits and a 33 kDa 
smaller one of the Pol II (POLR2A, POLR2C and POLR2E), CDK9, and 
several subunits of the Mammalian Mediator Complex (MED). The MED 
multiprotein is an evolutionarily conserved transcriptional regulator that 
plays important role in activation and repression of the Pol II transcription. In 
fact, it regulates the formation of transcription pre-initiation complex. It 
works as an adaptor that bridges Pol II and its several DNA binding 
regulatory proteins. MED transduces both positive and negative signals that 
turn on and off messenger RNA synthesis in response to the ever-changing 
microenvironment of the cell (Conaway et al, 2011). In line with this 
evidence, it has been recently proposed a new model in which the AF4 family 
proteins have a role in transcription initiation. Indeed, biochemical analysis 
identified a phosphoserine-rich (pSER) domain of AF4 that interacts with 
selective factor 1 (SL1). SL1 is a known component of Pol I pre-initiation 
complex (PIC) and it is constituted by TATA binding protein (TBP) and four 
TBP associated factor (TAF) of Pol I subunits. In MLL-FP dependent 
transcription, AF4 recruits SL1 and loads TBP onto TATA element promoter, 
activating transcription initiation by Pol I. The AF4 pSER domain, 
constituted by evolutionary conserved aminoacids 462-562, functions as a 
scaffold for SL1. When pSER binds to SL1, it is able to cause a 
conformational change of the target chromatin that leads to the substitution of 
TAF1B with transcription factor IIB (TFIIB). This substitution leads to the 
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formation of pre-initiation complex of Pol II that can initiate transcription 
(Okuda et al, 2015). 
A small fraction (8%) of AF4 interactors are proteins with predominant 
cytosolic localization. Among these proteins, there are SIAH1 and SIAH2. 
They are responsible for AF4 proteasome-dependent degradation because of 
their ubiquitin ligase activity. The interaction between SIAH and AF4 
proteins occurs at the ALF domain of AF4 and the SIAH binding domain of 
SIAH (Bursen et al, 2010). Other AF4 protein partners are 14-3-3 theta (θ) 
and 14-3-3 epsilon (ε), which belong to the 14-3-3 protein family (Esposito et 
al, 2011). 
 
 
1.5 14-3-3 family proteins: a focus on 14-3-3 θ isoform 
 
14-3-3 proteins are crucial regulators of intracellular signaling pathways. 
They are able to interact and regulate the activity of various target proteins. 
The different isoforms of 14-3-3 proteins accomplish different functions, 
which may be also tissue-specific (Aghazadeh et al, 2016). In mammalian, 
there are seven isoforms (β, γ, ε, σ, ζ, θ, η) encoded by closely related genes. 
14-3-3 proteins work as homo- or hetero-dimers; however, because of steric 
compatibility, not all the combination are possible. The tertiary structure is 
made up of nine antiparallel helices; these helices are arranged to form a "U-
shaped" structure. In a dimer, N-terminal helices of one subunit contact N-
terminal of the other subunit forming the “floor” of a central groove; the C-
terminal helices of two subunits contact one another forming “the wall” of 
the structure (Fig.10). 
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Figure 10. Representation of the “U-shaped” 14-3-3 dimer bound to a target 
phopshopeptide (in orange) (Rittinger et al, 1999). 
 
14-3-3s bind to specific phosphoSer (pSer) and phosphoThr (pThr) residues 
of target proteins (Mackintosh, 2004). It has been hypothesized that 14-3-3 
dimers bind to two sites on the same target protein with different affinity. A 
14-3-3 monomer binds to a first residue, which is indispensable for a stable 
14-3-3 interaction; binding to weaker secondary sites facilitates a 
conformational change, which exposes one or more regions of the protein 
that are inaccessible in the free or monomer-bound form (Yaffe et al, 2002). 
Through these interactions, 14-3-3 proteins play important roles in a wide 
range of crucial physiological and pathological processes. 
Notably, 14-3-3 proteins deregulation is associated to several human diseases 
and thus they undergo to a tight regulation in normal cells. One regulation 
mechanism of 14-3-3 proteins relies on the post-transcriptional modulation of 
its mRNA stability; accordingly, an emerging role in 14-3-3 regulation is 
attributed to microRNAs. Notably, 14-3-3θ is overexpressed in a wide range 
of human malignancies thus functioning as an oncogene. Indeed, this isoform 
is over-expressed in cancer cells, as well as patient samples (Zhao et al, 
2011). In particular, 14-3-3θ is overexpressed in metastatic breast carcinoma 
(Li et al, 2014) and is involved in astrocytoma tumor progression (Yan et al, 
2013). Recent studies conducted in our laboratory have demonstrated that 14-
3-3θ plays a crucial role in SEC/AEP dependent transcription. Indeed, in the 
nucleus, 14-3-3θ binds to AF4 and controls its localization on target 
chromatin, thus contributing to transcriptional activation in MLL-r leukemic 
transformation (Fioretti et al, submitted). Notably, a negative regulator of 14-
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3-3θ is MiR-27a, which is able to bind 3’-UTR of 14-3-3θ transcript and 
reduce protein levels (Scheibner et al, 2012). 
 
 
1.6 MicroRNA (miRNAs) and leukemia 
  
MicroRNAs (miRNAs) are non-coding RNAs that bind and regulate the fate 
of mRNAs. MiRNAs are transcribed from genomic DNA as long primary 
transcripts (pri-miRNAs) and then are processed by nuclear protein 
DROSHA into 60-70 nucleotides arranged to form a hairpin-shaped 
precursor RNAs (pre-miRNAs). Pre-miRNAs are then exported to the 
cytoplasm by EXPORTIN-5/Ran-GTP. After being exported to the cytosol, 
pre-miRNAs are further cleaved by DICER into a 22 nucleotide double 
strand mature miRNA. The following association of miRNA with RNA-
induced silencing complex (RISC) causes the pairing of one strand of the 
duplex miRNA with 3’-untranslated region (3’-UTR) of target mRNA 
sequences (Cai et al, 2009). Notably, target mRNA sites can be also located 
in 5'-UTR and in coding sequence (CDS) (Scheibner et al, 2012). Interactions 
between miRNA and mRNA target usually occurs in the so-called “seed” 
sequence, near to the miRNA 5’-terminus. The seed sequence is 6-8 
nucleotides long and is highly conserved among species. MiRNAs binding 
finally leads to either translational repression or degradation of the mRNA 
target (Fig. 11).  
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Figure 11. Representation of miRNA biogenesis: it begins inside the nucleus then its 
processing and maturation take place in the cytoplasm of an eukaryotic cell 
(http://atlasgeneticoncology.org). 
 
Numerous genes dispersed over the genome encode miRNAs. These genes 
are located in intergenic regions, in introns of protein-coding genes and in 
introns/exons of non-coding RNA genes. Some miRNA genes are clustered 
and tend to be co-expressed as polycistronic units; they may have functional 
relationship (Cai et al, 2009). Moreover, a single miRNA can regulate many 
mRNA targets and several miRNAs can regulate a single mRNA. MiRNAs 
control many biological processes, such as developmental transitions, 
neuronal patterning, apoptosis, adipogenesis, metabolism and hematopoiesis, 
in different organisms (Chhabra et al, 2010). 
Over the last years, increasing evidence about the involvement of miRNAs in 
regulation of hematopoiesis has been found. This regulation results in the 
targeting of genes involved in cell proliferation, metabolism and apoptosis 
(Sun et al, 2013). Aberrant expression of many different miRNAs has been 
observed in several cancers, including hematological malignancies. 
Interestingly, many of these miRNAs and their targets are implicated in 
leukemic stem cell development, differentiation and activation (Han et al, 
2011). Thus, changes in miRNA expression levels may play an important 
role in the genesis and evolution of ALL; so, they could be consider novel 
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biomarkers with potential use for diagnosis and tailored therapy in pediatric 
acute leukemia (Organista-Nava et al, 2016). 
Therefore, it is not surprising the evidence that MLL/AF4 regulates, and is 
itself a target, of miRNAs. For example, miR-142-3p functions as a growth 
suppressor in t(4;11) ALL, primarily through repression of MLL-AF4 
chimera expression (Dou et al, 2013). In addition, recent studies reveal that 
relapse may be triggered as a consequence of therapy-induced miRNA 
dysregulation and indeed there is a set of miRNAs associated with the risk of 
relapse in childhood ALL. This latter evidence also provides new insight into 
the molecular mechanisms of leukemia relapse (Han et al, 2011). 
 
 
1.6.1 MicroRNA-27a 
 
MicroRNA-27a (MiR-27a) is a member of a cluster composed by 2 other 
miRNAs, i.e. MiR-23a and MiR-24-2. The miR-23a~27a~24-2 cluster 
controls several processes during health and diseases. Indeed, its expression 
is linked to the modulation of cell cycle, proliferation, differentiation, 
hematopoiesis and cardiac hypertrophy (Chhabra et al, 2010). The cluster has 
altered expression in many diseases, among which there is ALL. 
It is well documented that miR-23a~27a~24-2 cluster derived from a 2.2 kb 
long single primary transcript, but its expression pattern may vary, depending 
on different biological conditions. In some cases, all three miRNAs have 
similar expression pattern and in others, one or two of these miRNAs are 
preferentially expressed, giving rise to contrasting phenotypes in different 
cell types.  
The transcription of miR-23a~27a~24-2 cluster can be Pol II dependent, 
however, the promoter, spanning from -603 and +36 bp, is a TATA-less 
promoter. In fact, it lacks not only TATA box, but also other promoter 
elements such as the initiator element, downstream promoter element (DPE), 
TFIIB recognition element (BRE), downstream core element (DCE), and 
MED.  
MiR-27a is the miRNA sandwiched between the MiR-23a and MiR-24-2 
(Fig.12). 
 
Introduction 
22 
 
 
Figure 12. Representation of the pre-miR hsa-23a~27a~24-2 cluster structure (Chhabra et 
al, 2010). 
 
Some cellular targets of MiR-27a are involved in cell cycle regulation, 
proliferation, apoptosis and differentiation. MiR-27a may have oncogenic 
and tumor suppressor functions. It is upregulated in estrogen receptor-
positive breast cancers and gastric cancers, whereas it is down-regulated in 
malignant melanoma and in several acute leukemia cell lines and primary 
samples (Chhabra et al, 2010; Scheibner et al, 2012).  
Very interestingly, low MiR-27a expression levels were detected in 
diagnostic specimens from leukemia patients who subsequently relapsed. 
Indeed, it has been demonstrated that MiR-27a is relevant to treatment 
outcome in vivo and its downregulation promotes ALL relapse by regulating 
genes in classical drug or multi-drug resistance pathways. Thus, MiR-27a 
downregulation leads to the accumulation of MULTI DRUG RESISTANCE 
PROTEIN 1 (MDR1), which, in turn, might promote leukemic cell 
proliferation or drug resistance, leading to leukemia recurrence (Han et al, 
2011).  
The relapse-associated miRNAs, as MiR-27a, and their targets might be used 
to optimize anti-leukemia therapy and might be novel targets for the 
development of new leukemia countermeasures. 
Very interestingly, a known target of MiR-27a is RUNX1, a transcription 
factor that functions as key regulator of definitive hematopoiesis in embryo 
and adult (Ben-ami et al, 2008). It is involved in the t(4;11) ALL 
pathogenesis; indeed, the RUNX1 gene is directly activated by MLL-AF4 and 
the RUNX1 protein interacts with the product of the reciprocal AF4-MLL 
translocation, thereby contributing to leukemic transcription program 
(Wilkison et al, 2013).
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2. AIM 
Over the past decade, alterations in biogenesis and activity of microRNAs 
(miRNAs) have been identified in cancer pathogenesis. Accordingly, some 
clinical trials use miRNA profiling for patient prognosis and clinical 
response, and the first miRNA mimic entered the clinic for cancer therapy in 
2013. Considering the growing involvement of miRNAs in human 
tumorigenesis, this PhD thesis aims to investigate the potential role of MiR-
27a in the molecular pathogenesis of t(4;11) ALL. Indeed, MiR-27a functions 
as tumor suppressor in various human leukemias and one of its targets is 14-
3-3θ. Previous studies conducted in our laboratory demonstrated that the 
scaffold protein 14-3-3θ is a direct interactor of the AF4 protein and 
functions as an oncogene in t(4;11) leukemia cell lines (Esposito et al, 2011; 
Fioretti et al, submitted). The chromosomal translocation t(4;11) causes an 
aggressive form of acute lymphoblastic leukemia (ALL) which is particularly 
common in infants. In t(4;11) ALL, the MLL gene (KMT2A), on chromosome 
11, is involved in a translocation with the AFF1 gene, on chromosome 4, and 
the resulting fusion gene expresses the chimeric oncoprotein MLL-AF4. 
Notably, MLL can translocate with different partner genes and all the 
resulting fusion proteins are potent oncogenes that cause sustained 
transactivation of most MLL target genes, including the HOX genes 
(Yokoyama et al, 2010), and many efforts have been made to understand the 
pathogenic mechanisms leading to hematopoietic progenitors transformation 
in the MLL-related (MLL-r) leukemia. MLL wild type is a transcriptional 
factor with histone methyltransferase activity that marks chromatin of active 
genes. AFF1, the main MLL translocation partner gene, encodes the nuclear 
protein AF4 that forms, with p-TEFb and ENL, the SEC/AEP complex, 
which is physiologically recruited by MLL wild type on target gene 
promoters, thereby enabling transcription initiation and elongation 
(Yokoyama et al, 2010; Yokoyama, 2017). In MLL-r leukemias, oncogenic 
chimeras constitutively recruit the SEC/AEP complex leading to aberrant 
expression of genes that are downregulated in normal hematopoiesis. Various 
studies demonstrated that AF4 has a key role in recruitment of the SEC/AEP 
complex in physiological condition and in MLL-r leukemia (Yokoyama et al, 
2010) and identification of AF4 protein interactors strongly contributed in 
understanding its function. Accordingly, our previous studies have 
demonstrated that 14-3-3θ binds AF4 and favours its recruitment on MLL-
AF4 target gene promoters; hence we proposed 14-3-3θ downregulation as 
potential therapeutic strategy to treat t(4;11) ALL. Because 14-3-3θ is 
downregulated by MiR-27a, we analyzed consequences of MiR-27a 
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overexpression on 14-3-3θ levels and MLL-AF4 activity, in t(4;11) cell lines. 
Moreover, we looked for known and unknown MiR-27a targets involved in 
the t(4;11) leukemia pathogenic mechanism and validated the putative novel 
targets by luciferase assay. Furthermore, we measured the impact of MiR-27a 
overexpression on clonogenic capability, proliferation and apoptosis rate of 
t(4;11) cells, thereby analyzing the resulting leukemia phenotype. Lastly, we 
analyzed relative expression level of MiR-27a in patients affected by t(4;11) 
ALL and in patients affected by a type of leukemia with very benign 
prognosis. Overall, data we obtained give proof of concept that enhancing 
MiR-27a cellular level could represent an innovative therapeutic strategy to 
treat this dismal type of leukemia. 
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3. MATERIALS AND METHODS 
3.1 Cell lines  
 
The cell lines were obtained from cell culture facility of the CEINGE - 
Biotecnologie Avanzate and the IRCCS SDN (Naples, Italy). RS4;11 acute 
lymphoblastic leukemia cells were grown in α-modification minimum 
essential medium (MEM) (Sigma-Aldrich), supplemented with 10% FBS and 
1% penicillin/streptomycin. MV4;11 acute monocytic leukemia cells and 
REH acute lymphoblastic leukemia cells were grown in RPMI (Sigma-
Aldrich), supplemented with 10% FBS and 1% penicillin/streptomycin. SEM 
acute lymphoblastic leukemia cells were grown in Iscove's Modified 
Dulbecco's Medium (IMDM) (Lonza) supplemented with 10% FBS and 1% 
penicillin/streptomycin. Leukemia cells were grown at 37°C in 5% CO2 and 
were subcultured as suggested by Leibniz-Institut DSMZ catalogues. The 
RS4;11, MV4;11 and SEM are t(4;11) leukemia cell lines. 
 
 
3.2 Transfection 
 
For MiR-27a transfection, hsa-pre-miR-27a-3p or has-pre-miR-negative 
control (Ambion) was added to 1.0 x 10
7
 cells at a final concentration of 
50nM in a final volume of 100μL of opti-MEM (Gibco), not supplemented.  
For luciferase reporter assay transfection, 10µg of PsiCHEK-2 construct was 
added to 1.0 x 10
7 cells in a final volume of 100μL of opti-MEM (Gibco), not 
supplemented. Cells were transfected by using the Gene Pulser Xcell™ 
Electroporation System (BioRad). Electroporation conditions were: voltage 
330 or 500 mV, for MiR-27a or plasmids, respectively; impulse length, 1 or 3 
ms; number of pulses, 1; interval between impulses, 0. 
 
 
3.3 Quantitative RT-PCR (RT-qPCR) analysis 
 
3.3.1 RNA extraction 
 
Total RNA was extracted from cells with RNeasy Mini kit (Qiagen), 
according to the manufacturer’s protocol. The concentration of the RNA was 
determined using NanoDrop™ 2000/2000c Spectrophotometers 
(ThermoFisher Scientific).  
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3.3.2 Reverse transcription (RT) and real time - quantitative PCR (qPCR) 
analysis 
 
For reverse transcription of MiR-27a, 150 ng of total RNA from cultured 
cells, or 40 ng of total RNA from patient samples, were retro-transcribed 
using TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems), 
according to manufacturer’s protocol. For the whole RNA reverse 
transcription, 200 ng of total extracted RNA were using. Reactions were 
performed using SuperScript™ III First-Strand Synthesis System (Invitrogen) 
with random hexamers. Reactions were perfrmed as suggeste by the 
manufacturer’s protocol. 
For real time qPCR of MiR-27a, TaqMan® Universal Master Mix II were 
used. According to the manufacturer’s protocol, 1.33µL of each specific 
cDNA sample and 1 µL of TaqMan probe (TaqMan® MicroRNA Assays) 
specific for the MiR-27a or for the internal control, U18, were used. 
For real time qPCR of total cDNA, iQ™ SYBR ® Green Supermix was used. 
According to the manufacturer’s protocol, 1μl of cDNA and 10µΜ of gene-
specific primer pairs were used (Tab.1). Real time qPCR was carried out in 
iCycler iQ Real Time PCR Thermal Cycler (Bio‐Rad). Relative gene 
expression was normalized to POLR2A and ACTB genes and determined by 
2
-ΔΔCt
 method. Average values from at least three independent experiments 
were graphically reported as relative units (R.U.). 
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Primers Forward Reverse 
14-3-3θ 5’ – AGCAGAAGACCGACACCTC – 3’ 5’ – ATCCAACAATTCCAGCACCG – 3’ 
HOXA9 5’ TGTGGTTCTCCTCCAGTTGATAGAGCG 3’ 5’ – TCGGTGAGGTTGAGCAGTCGAG – 3’ 
HOXA7 5’ – CGCCAGACCTACACGCG – 3’ 5’ – CAGGTAGCGGTTGAAGTGGAA – 3’ 
MEIS1 5’ – AGCATCTAACACACCCTTACC – 3’ 5’ – CCTTGACTTACTGCTCGGTTG -3’ 
AFF1 5’ – CTACAAAGACTCTCAGCATG – 3’ 5’ – TTCTCTGGGGTTTGTTCGACTG – 3’ 
ACTB 5’ – CGACAGGATGCAGAAGGAGA – 3’ 5’ – CGTCATACTCCTGCTTGCTG - 3’ 
POLR2A 5’ – CAACGCACACATCCAGAACG – 3’ 5’ – TCCTTGACTCCCTCCACCAC – 3’ 
Table 1. Primer sequences, designed using OligoExplorer 1.2 tool. 
 
 
3.4 Proteins analysis 
 
3.4.1 Protein extraction 
 
Whole-cell protein extracts (WCE) for western blot analysis were prepared 
by disrupting cells using lysis buffer [50mM Tris/HCl pH 8, 150mM NaCl, 
0.5 % NP-40, 2mM EDTA pH 8, 1mM Na3V04, 10mM NaF, 0.1% (v/v) 
protease inhibitor cocktail (Sigma Aldrich)]. Cells were incubated on ice for 
30 min, then centrifuged at 16,000 rcf at 4°C for 5 min. Supernatant 
represented the WCE. 
 
 
3.4.2 Western blot 
 
Gel electrophoresis was performed in a SDS-polyacrylamide gel and 
transferred to nitrocellulose membrane (BioRad), by electro-blotting. 
Binding to proper antibody was visualized using the ECL detection system 
(GE Healthcare). All images were acquired using X-Ray films (SantaCruz 
Biotechnologies). Densitometric analysis of images was carried out by using 
ImageJ software. Antibody concentrations for the western blot were chosen 
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according to the manufacturers ‘recommendations. All the antibodies used 
are indicated below. 
 
 
3.4.3 Antibodies 
 
Rabbit polyclonal anti-14‐3-3θ, mouse monoclonal anti-tubulin, mouse 
monoclonal anti-vinculin (Santa Cruz Biotechnology); rabbit polyclonal anti-
AF4 (Bethyl Laboratories); mouse monoclonal anti-MLL
N
 and anti-MLL
C
 
(Merck Millipore); rabbit polyclonal anti-RUNX1 (Cell Signaling 
Technology); horseradish peroxidase-conjugated anti-mouse and anti-rabbit 
IgG secondary antibodies (GE Healthcare). 
 
 
3.5 Molecular Cloning 
 
3.5.1 Insert and vector preparation 
 
Since AFF1-3’-UTR is 5353bp long, to enhance the cloning efficiency it was 
amplified in three overlapping fragments. Amplification were performed 
from genomic DNA, using PrimeSTAR GXL DNA Polymerase (Takara), as 
indicate by manufacturer’s protocol. Specific primer sequences are listed in 
Table 2. PCR products were visualized by electrophoresis on 1% agarose gel 
and recovered using Illustra GFX PCR DNA and Gel Band Purification Kits 
(GE Healthcare). Concentration was determined spectrophotometrically. 
Inserts and psiCHECK-2 vector were digested with the appropriate restriction 
endonucleases. Digestions were carried out with SgF1 (Promega) or XhoI 
(Roche) and NotI (Roche), according to the manufacturer’s 
recommendations. Finally, quantification of digested inserts and vector was 
performed using NanoDrop™ 2000/2000c Spectrophotometers 
(ThermoFisher Scientific). 
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FRAGMENT PRIMERS 
3’-UTR-1 
(1819bp) 
Forward - SgfI 
5’-GCCGGCGAT/CGCTTTGCACATTGGAAGCCTCA-3' 
Reverse - NotI 
5’-GCCGGC/GGCCGCTAAACATGAGGGACCAGACC-3’ 
3’-UTR-2 
(1915bp) 
Forward - XhoI 
5’-GCCGC/TCGAGAGTGTGAGTGGTCTGTGTGA-3'  
Reverse - NotI 
5’-GCCGGC/GGCCGCCAAAAAAACCCGAAAGCCCA-3’ 
3’-UTR-3 
(1872bp) 
Forward - XhoI 
5’-GCCGC/TCGAGATACCGCTGTGTTTGTTTCG-3' 
Reverse - NotI 
5’-GCCGGC/GGCCGCCAACCCCAATGATTTCTCGA-3’ 
Small-AFF1-3’-UTR 
(584bp) 
Forward - XhoI 
5'-GCCGC/TCGAGTTCCCAAAGGCAAAATCTGT -3’ 
Reverse - NotI 
5’- GCCGGC/GGCCGCATAAGTGCGGTCCAATCTGT -3’ 
Table 2. Primer used to amplify AFF1- 3’-UTR for luciferase reporter assay. In blue, anchor 
nucleotides; in red, restriction enzyme’s recognition site; in black, specific AFF1 sequence. 
 
 
 
3.5.2 Ligation and bacterial transformation 
 
For each cloning procedure, three different ligation reactions were 
performed. The first reaction contained only the digested vector, to control 
for vector background; the second included digested vector and T4 DNA 
ligase, to evaluate cutting efficiency of a single restriction enzyme; the third 
reaction contained vector and insert (1:3 ratio). 
Bacterial transformation was performed using E.coli Top-ten cells made 
competent with the CaCl2 protocol. In detail, 100 μl of competent cells were 
incubated on ice for 30 min with 20 μl of each ligation mixture. A heat shock 
(45 sec at 42°C followed by immediately transfer to ice, for 2 min) was then 
performed, to induce entry of plasmid DNA into bacterial cells. Next, 250 μl 
of LB culture medium (Bacto-Tryptone, Bacto Yeast-Extract, NaCl) was 
added and the mixture was incubated at 37°C for 1 h and 30 min with shake. 
All reactions were then plated on bacterial agar plates containing 100 mg/ml 
of ampicillin. After over-night incubation at 37°C, plasmid DNA from 
positive colonies was extracted by using Qiaprep spin miniprep kit (Qiagen), 
digested with restriction enzymes and analyzed by sequencing. Larger 
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amount of recombinant plasmids was obtained according to 
recommendations of the Plasmid Maxi Kit (Qiagen). Plasmid DNA 
concentration was determined by NanoDrop spectrophotometric reading.  
 
 
3.6 Site-directed mutagenesis 
 
Mutagenesis was performed using the QuickChange kit (Stratagene) and 
auto-complementary primers, according to the manufacturer’s instruction. 
Primers used to obtain mutated forms of psiCHECK-2-AFF1-3’-UTR were 
designed by using PrimeX online tool (Tab.3). 
 
 Primer sequence 
Forward 5' – GTGTTTAATGTTTCTGTCCTTTATCTGTATTATTGAATTTAAGAGCCCTGC -  3' 
Reverse 5' – GCAGGGCTCTTAAATTCAATAATACAGATAAAGGACAGAAACATTAAACAC - 3' 
 
Table 3. Sequences of mutagenesis primers 
 
 
 
3.7 Luciferase reporter assays 
 
RS4;11 cells were co-transfected, as described before, with pre-MiR-27a and 
the psiCHECK-2-AFF1-3’-UTR or the mutated one (each with the 
appropriate controls). After 24 h, cells were harvested and assay was 
performed, using Dual-Luciferase® Reporter (DLR) Assay System, 
according to the manufacturer’s recommendation. In DLR Assay System, 
Renilla (Renilla reniformis) represents the experimental reporter and Firefly 
(Photinus pyralis) luciferase provides an internal control. 
 
 
3.8 Chromatin Immunoprecipitation (ChIP) Assay 
 
RS4;11 cells (30×10
6
 for each experimental system) were transfected with 
MiR-27a as described before and after 36 h were fixed in optiMEM medium 
containing 1% formaldehyde for 10 min at room temperature; the reaction 
was stopped by glycine quenching (125 mM final concentration). Nuclei 
were collected, digested in 50 mM Tris‐HCL pH 8.1, 10 mM EDTA, 10% 
SDS, and then subjected to sonication (6 cycles of 30 s of sonication and 30 s 
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without sonication) using a Microson XL ultrasonic cell disruptor (Misonic). 
Protein-linked DNA fragments (ranging from 100-600 bp) were incubated 
overnight at 4°C with appropriate antibodies, then mixed with protein-G 
magnetic beads (Santa Cruz Biotechnology) and incubated for 2 h. Beads 
were washed with ChIP buffer (10mM Tris-HCl pH 8.1, 1mM EDTA, 10% 
SDS, 0.5% EGTA, 140mM NaCl, 10X Na-deoxycholate, 100X Triton). 
Immunoprecipitates were dissolved in elution buffer (0.5M EDTA, 1M Tris-
HCl pH 8.0) and DNA harvested by phenol/chloroform/isoamyl alcohol 
extraction and ethanol precipitation. Real time quantitative PCR (qPCR) was 
performed with 1μL of DNA using a custom-made primer set, as already 
described (Yokoyama et al, 2010).  
 
 
 
3.9 Cell viability assay 
 
RS4;11, SEM and MV4;11 (4 × 10
4
 per well) leukemia cells were transfected 
with pre-MiR-27a or pre-MiR-negative control, and seeded in a 96-well 
plate. Cell proliferation was assessed using Cell Counting Kit 8 (CCK8), 
according to the manufacturer’s recommendation. To obtain a cell growth 
curve, absorbance was measured at 540 nm 24h-48h-72h after transfection, 
for each analyzed cell lines, using a Spectramax spectrophotometer 
(Biocompare). After appropriate testing, normalization of the cell viability, 
for each system, was performed using non-electroporated cells. The 
percentage of viability cells is expressed according to the equation:  
Viability: [(sample well mean OD/background mean OD) / (control well 
mean OD/background mean OD)] x 100% 
 
 
3.10 BrdU cell proliferation assay 
 
RS4;11 cells transiently transfected with pre-MiR-27a or pre-MiR-negative 
control were plated in 24 multiwell (1 x 10
6 cells/ml) in αMEM, with 10% 
FBS and 1% penicillin/streptomycin. Forty-eight hours after transfection, 
cells were treated with 10μl BrdU [1mM in 1x Dulbecco's phosphate-
buffered saline (DPBS)]/ml of media for 45 min and stained with 7-
aminoactomycin D (7-AAD) (BD Pharmingen). Cytofluorimetric analysis 
was carried out using the FACS Calibur system (Becton Dickinson). 
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3.11 Apoptosis assay 
RS4;11 cells were transfected with MiR-27a as described before; 72 h after 
transfection cells were incubated in annexin binding buffer (10mM HEPES, 
pH 7.4; 140mM NaCl; 2.5mM CaCl2) and centrifuged at 300xg at 4°C for 10 
min. A solution of Annexin V-FITC (1:1000) (Miltenyi Biotec) and 
Propidium Iodide (PI) (2µg/mL) (BD Biosciences) was added to the cells. 
Positive staining was detected by flow cytometry, using FACS Calibur 
system (Becton Dickinson). 
 
 
3.12 Colony-formation assay 
RS4;11 cells were transiently transfected with pre-MiR-27a or pre-MiR-
negative control, as described before. After 24 h, transfected cells (1.2 x 10
4
) 
were cultured in the MethoCult medium (STEMCELL Technologies), a 
semi-solid methylcellulose-based media, in a 6 well plate. Procedure was 
performed according to the manufacturer’s protocol. 
After two weeks, obtained colonies was analyzed using LEICA DMIL LED 
Microscope, Objective 20X.  
 
 
3.13 Statistical analysis 
The data from repeated experiments were analyzed using one-way Student‘s 
T-test (for independent samples). 
Results 
32 
 
4. RESULTS 
 
4.1 MiR-27a and 14-3-3θ expression level in t(4;11) leukemia cell lines 
 
Our study started from literature data reporting that MiR-27a levels are low in 
several preB- and T-ALL cell lines. To evaluate MiR-27a baseline expression 
levels in t(4;11) leukemia cell lines (i.e. RS4;11, SEM and MV4;11) we 
performed a RT-qPCR with MiR-27a-specific TaqMan
TM 
probe. As 14-3-3θ 
is a known target of MiR-27a and considering its functional role in t(4;11) 
leukemia (Fioretti et al, submitted), we simultaneously evaluated 14-3-3θ 
transcript levels in the same cell lines, by RT-qPCR. Results revealed an 
inverse correlation between MiR-27a and 14-3-3θ transcript levels, which is 
particular relevant in t(4;11) leukemia cells (Fig.13A,B). 
 
 
Figure 13. RT-qPCR to measure (A) MiR-27a and (B) 14-3-3θ levels in different leukemia 
cell lines. PBL were used as reference system; REH and 697 cell lines were the positive and 
HL60 the negative control system. Normalization of MiR-27a level was performed to U18 
endogenous control gene, whereas 14-3-3θ level was normalized to β-actin and RNA Pol2A 
endogenous control genes. Relative gene expression was determined using the 2
-ΔΔCt 
method. 
Experiments were performed in triplicate. Error bars indicate standard deviations. Statistical 
significance was calculated by one-way two tail paired T-test. p‐ value are indicated as 
follows: *=p<0.05, **=p<0.01, *** p =<0.005, NS: not statistically significant. 
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In order to evaluate the potential effects of MiR-27a increase in the context of 
t(4:11) leukemia pathomechanism, we transiently transfected RS4;11 cells 
with pre-MiR-27a, by electroporation. To evaluate the expression profile of 
MiR-27a, we measured its levels 18, 24 and 36 h after transfection (Fig.14A), 
by RT-qPCR. We also performed western blot analysis and evaluated 14-3-3θ 
protein amounts after MiRNA transfection. Results indicated that 14-3-3θ 
decreased as a consequence of MiR-27a overexpression (Fig.14B). 
Overall, these experiments indicate that MiR-27a targets 14-3-3θ also in 
RS4;11 cell lines. 
 
 
Figure 14. (A) RT-qPCR to monitor the expression level of the MiR-27a. 18-24-36 h after 
transfection in RS4;11 cells. Normalization was performed to U18 endogenous control gene. 
Relative gene expression was determined using the 2
-ΔΔCt 
method. (B) Western Blot and 
densitometric analysis to measure 14-3-3θ protein level 36 h after MiR-27a transfection, on 
RS4;11 WCE. Densitometric measure was normalized to α-tubulin. Results are the mean 
values from three independent experiments. Error bars indicate standard deviations. 
Statistical significance was calculated by one-way two tail paired T-test. p‐ value are 
indicated as follows: *=p<0.05.  
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4.2 AF4 and MLL-AF4 are novel targets of MiR-27a 
 
Searching for some other potential MiR-27a targets involved in leukemia 
pathogenesis, we performed a bioinformatic analysis by interrogating proper 
miRNA prediction tools (i.e. TargetScan, microRNA.org, Diana tools). 
TargetScan yielded a seed sequence of 7-mer in AFF1-3’-UTR, at position 
2884-2890 from the stop codon. The MicroRNA.org interface considered the 
same sequence and yielded a 6-mer match in position 2870, which 
corresponded to TargetScan match, and another in position 5118 of AFF1 3’-
UTR. DianaTarbase considered several putative 6-mer and 7-mer seed 
sequences, among which the seed in position 2869-2889 was shared with the 
aforementioned databases (Appendix A). The score associated to each 
putative seed sequence was different, according to the different score system 
parameters adopted by the tools. Thus, our bioinformatic analysis indicated 
that transcript of AFF1 could be a potential target of MiR-27a.  
To demonstrate this hypothesis, we evaluated AF4 protein levels, after 
overexpression of MiR-27a in t(4;11) leukemia cells. To this aim, we 
transfected RS4;11 cells with pre-MiR-27a or pre-MiR-negative control; cells 
were then harvested and total proteins extracted and analyzed by western blot. 
Results revealed a strong reduction of AF4 protein levels as consequence of 
MiR-27a overexpression, in comparison to the control cells (Fig.15A). 
Because AFF1 shares the same 3’-UTR with the KTLM2-AFF1 fusion gene, 
we verified weather MiR-27a affected also MLL-AF4 chimera expression, by 
measuring its protein level in the same cell samples. Very interestingly,  
MLL-AF4 protein level significantly decreased after MiR-27a transfection 
(Fig.15B). 
Notably, MiR-27a overexpression caused a decrease in AFF1 transcript levels 
of about 40%, thereby suggesting that MiR-27a likely works by inducing 
AFF1 mRNA degradation (Fig.15C). 
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Figure 15. Western Blot and densitometric analysis to evaluate (A) AF4 and (B) MLL-AF4 
protein levels after MiR-27a transfection, in RS4;11 WCE. Densitometric measure was 
normalized to α-tubulin. (C) RT-qPCR to measure AF4 levels after MiR-27a transfection. 
Normalization was performed to β-actin and RNA Pol2A endogenous control genes. Relative 
gene expression was determined using the 2
-ΔΔCt  
method. Each experiment was performed in 
triplicate. Error bars indicate standard deviations. Statistical significance was calculated by 
one-way two tail paired T-test. p‐ value are indicated as follows: **=p<0.01. 
 
 
To identify the MiR-27a target sequence within the AFF1 transcript, we 
cloned the large AFF1-3’-UTR in the psiCHECK-2 vector. Since AFF1-3’-
UTR length (5371bp) could affect cloning efficiency, we generated three 
different constructs, which, overall, contained three overlapping fragments 
that covered the entire AFF1-3’-UTR (Fig.16A). Preliminary luciferase assay 
results indicated that the central fragment of AFF1-3’-UTR was the best 
candidate to contain the putative seed sequence (APPENDIX B). This 
information was also consistent with the bioinformatic analysis that, 
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according to all the interrogated databases, localized the putative seed 
sequence in this portion of AFF1-3’-UTR. 
Therefore, we cloned, in the psiCHECK-2 vector, the central fragment of 
AFF1-3’-UTR (584 bp long) that contained the 7-mer sequence identified by 
all the interrogated databases (Fig.16B). To create a negative control vector, 
we modified the putative 7-mer seed sequence by site-directed mutagenesis of 
the wild type construct and obtained the Mut_psiCHECK-2-AFF1-3’-UTR. 
Using these two constructs, we performed a dual-luciferase reporter assay to 
determine whether the predicted MiR-27a-binding sequence of AFF1 
transcript was a functional target site. 
To this aim, the reporter plasmid psiCHECK-2-AFF1-3’-UTR and the pre-
MiR-27a or the pre-MiR-negative control were co-transfected into RS4;11 
cells. The luciferase reporter assay demonstrated that co-transfection of 
psiCHECK-2-AFF1-3’-UTR vector and pre-miR-27a reduced Renilla 
activity, compared to the MiR-negative control. In contrast, co-trasfection of 
Mut_psiCHECK-2-AFF1-3’-UTR vector with both pre-MiR-27a and pre-
MiR-negative control did not result in reduction of Renilla activity (Fig.16C). 
To further demonstrate that AFF1 mRNA is an actual novel target of MiR-
27a, we transfected RS4;11 cells with anti-MiR-27a, which binds to MiR-27a 
and blocks its function. After anti-MiR-27a transfection, AF4 protein levels 
are 2-fold higher than in control cells, which were transfected with the anti-
MiR-negative control (Fig.16D).  
These data ultimately demonstrate that MiR-27a directly binds AFF1-3’-
UTR, thereby reducing AF4 and MLL-AF4 protein levels. 
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Figure 16. (A) Graphical representation of length and position of the three AFF1-3’-UTR 
fragments we cloned within the psiCHECK-2 vector for the Luciferase reporter assay. (B) 
Alignment of the putative seed sequence in AFF1-3’-UTR and MiR-27a. Bases in bold were 
mutated to obtain the negative control vector, for the Luciferase reporter assay. (C) 
Luciferase reporter assay to measure Renilla activity, after MiR-27a transfection in RS4;11 
cells, using both wild type and Mut_psiCHECK-2-AFF1-3’-UTR. Normalization was 
performed to firefly Luciferase activity. (D) Western Blot and densitometric analysis to 
measure AF4 protein level after anti-MiR-27a transfection, on RS4;11 WCE. Densitometric 
measure was normalized to vinculin. Results are the mean values from three independent 
experiments. Error bars indicate standard deviations. Statistical significance was calculated 
by one-way two tail paired T-test. p‐ value are indicated as follows: *=p<0.05; **=p<0.01. 
 
 
4.2.1 MiR-27a targets RUNX1 in RS4;11 leukemia cell line 
 
Among MiR-27a targets, bioinformatic analysis also revealed the known 
target RUNX1. Taking into account the crucial role of RUNX1 in the t(4;11) 
leukemia molecular mechanisms, we analyzed the effect of MiR-27a 
overexpression on RUNX1 protein level, in RS4;11 cells. To this aim, we 
transfected RS4;11 cells with pre-MiR-27a or pre-MiR-negative control. 
Thirthy-six hours after transfection, we harvested cells and extracted total 
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proteins to perform a western blot analysis. Results revealed a reduction of 
RUNX1 protein level as consequence of MiR-27a overexpression, thus 
demonstrating that this MiRNA is able to target and down-regulate RUNX1 
also in the t(4;11) leukemia context (Fig.17). 
 
 
Figure 17.  Western Blot and densitometric analysis to evaluate RUNX1 protein level 36 h 
after MiR-27a transfection, in RS4;11 WCE. Densitometric measure was normalized to α-
tubulin. Each experiment was performed in triplicate. Error bars indicate standard 
deviations. Statistical significance was calculated by one-way two tail paired T-test. p‐ value 
are indicated as follows: **=p<0.01. 
 
 
4.3 MiR-27a impairs MLL-AF4 chimera’s activity in t(4;11) cell lines 
 
Previous experiments showed that MiR-27a is able to downregulate 14-3-3θ, 
RUNX1, AF4 and MLL-AF4, crucial players in molecular mechanisms that 
sustain leukemic transformation. Thus, we assessed the effects of MiR-27a 
overexpression on transcription of known chimera target genes, namely 
HOXA9, HOXA7 and MEIS1, in the three t(4;11) cell lines (RS4;11, SEM and 
MV4;11). We transfected the cells with pre-MiR-27a or pre-MiR-negative 
control; cells were then collected and total RNA was extracted (see 
APPENDIX C to MiR-27a level after transient transfection in SEM and 
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MV4;11 cell lines). Expression level of the specific genes was analyzed by 
real time RT-qPCR. Results revealed that overexpression of MiR-27a caused 
a significant decrease in HOXA9, HOXA7 and MEIS1 expression 
(Fig.18A,B,C). This effect was specific because MiR-27a overexpression did 
not reduce expression level of these genes in REH cells, a non MLL-r 
leukemia cell line (Fig.18D). 
 
 
Figure 18. RT-qPCR analysis to measure HOXA9, HOXA7 and MEIS1 expression levels in (A) 
RS4;11, (B) SEM, (C) MV4;11, (D) REH, after MiR-27a transfection. The REH cell line was used 
as negative control system. Relative gene expression was normalized to β-actin and PolR2A 
endogenous genes and determined using the 2
-ΔΔCt
 method. The shown results are the mean values 
from three independent experiments. Error bars indicate standard deviations. Statistical 
significance was calculated by one-way two tail paired T-test. p‐ value are indicated as follows: 
*=p<0.05; **=p<0.01, *** p =<0.005, NS: not statistically significant. 
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4.4 MiR-27a impairs MLL-AF4 interaction with HOXA9 promoter in 
RS4;11 cells 
 
Since we demonstrated that MiR-27a overexpression causes a reduction in the 
MLL-AF4 protein levels and also reduces expression of the main chimera 
target genes, we performed, in RS4;11, a chromatin immunoprecipitation 
(ChIP) assay in order to evaluate effectiveness of MLL-AF4 binding to 
HOXA9 gene promoter (HOXA9pr), after MiR-27a transfection. To this aim, 
chromatin was immunoprecipitated using 2 different anti-MLL antibodies: 
one recognizes the N-terminal portion of both wild type MLL protein and 
MLL-AF4 chimera (MLL
N
); the other binds to the C-terminal region of MLL 
(MLL
C
), thus identifying only wild type MLL protein. A pool of non-specific 
IgG was the negative control. We then performed RT-qPCR analysis to 
measure the amount of HOXA9pr immunoprecipitated by anti-MLL
N
 and 
anti-MLL
C
; the same analysis was performed for β-actin promoter (ACTBpr), 
as negative control. The HOXA9pr element we analyzed was already 
validated as chimera’s target (Yokoyama et al, 2010; Fioretti et al, 
submitted). Results showed that percentage of HOXA9pr in chromatin 
precipitated with anti-MLL
N
 was significantly lower in RS4;11 cells 
transfected with pre-MiR-27a than in control cells, which were transfected 
with pre-MiR-negative control. Notably, there was not significant difference 
in the percentage of HOXA9pr in chromatin precipitated with anti-MLL
C 
(Fig.19). These results indicate that MiR-27a transfection affects only binding 
of MLL-AF4, not of MLL wild type, to HOXA9pr. 
 
 
 
 
Results 
41 
 
 
Figure 19. ChIP assay to evaluate the interaction of MLL-AF4 protein to HOXA9pr. (A) Data are 
expressed as percentage of HOXA9pr and ACTBpr in immunoprecipitated chromatin respect to the 
INPUT. IgG is the negative control. Interaction of (B) MLL-AF4 and (C) MLL wild type with 
HOXA9pr after the MiR-27a transfection. Results represent the average of three independent 
experiments. Error bars indicate the standard deviations. Statistical significance was calculated by 
one-way two tail paired T-test. p-value are indicated as follows: *** p =<0.005, NS: not 
statistically significant. 
 
 
4.5 MiR-27a affects cell viability, proliferation, apoptosis and clonogenic 
capacity of t(4:11) leukemic cells 
 
Considering that MiR-27a targets the most relevant components of the 
transcriptional machinery in t(4;11) leukemia, we investigated the effects of 
MiR-27a overexpression on cell viability. To this end, we performed a 
viability assay using the cell counting kit 8 (CCK8). The assay was performed 
in three t(4;11) leukemic cell lines (RS4;11, SEM and MV4;11) transfected 
with pre-MiR-27a or pre-MiR-negative control. In order to obtain a cell 
growth curve, absorbance was measured at 540 nm, 24h-48h-72h after 
transfection. Results were expressed in percentage of viable cells and showed 
that, for all analyzed cell lines, already 24 hours post-transfection, viable cells 
were fewer than in the negative control (Fig.20A,B,C). Notably, transfection 
with anti-MiR-27a increased cell viability (Fig.20D,E,F), thereby 
demonstrating that changes in cell viability specifically depends on MiR-27a. 
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Figure 20. Cell count kit 8 (CCK8) assay to determinate viability of (A) RS4;11, (B) SEM, 
(C) MV4;11 leukemia cells after transfection of MiR-27a. Viability of (D) RS4;11, (E) SEM, 
(F) MV4;11 cells by using anti-MiR-27a. Data are shown as mean of three independent 
experiments. Error bars indicate the standard deviations. Statistical significance was 
calculated by one-way two tail paired T-test. p-value are indicated as follows: *=p<0.05, 
**=p<0.01, *** p =<0.005.  
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To better analyze the effects of MiR-27a overexpression on cell proliferation, 
we also performed a 5-bromo-2’-deoxyuridine (BrdU) assay in RS4;11 cells 
48 hours after transfection with pre-MiR-27a or pre-MiR-negative control. 
Results showed that MiR-27a overexpression strongly reduced the number of 
cells in S phase of cell cycle, which represented proliferating cells (Fig.21). 
 
 
Figure 21. RS4;11 cell proliferation analyzed by BrdU incorporation assay, 48 h after MiR-
27a transfection. Results were obtained by cytofluorimetric analysis and graphically 
represented as cytograms (top panels) and bar graph (bottom panel). Data are the mean of 
three independent experiments. Error bars indicate the standard deviations. Statistical 
significance was calculated by one-way two tail paired T-test. p-value are indicated as 
follows: *=p<0.05.  
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Since HOXA9 knockdown induces apoptosis in the MLL-leukemia cell lines 
(Faber et al, 2009) and 14-3-3 proteins belong to a family of anti-apoptotic 
proteins (Aghazadeh et al, 2016), we wondered whether overexpression of 
MiR-27a has a pro-apoptotic effect. Accordingly, we performed an apoptosis 
assay in RS4;11 cells transiently transfected with MiR-27a, using annexin V-
FITC-conjugated. RS4;11 cells were transfected with pre-MiR-27a or pre-
MiR-negative control and harvested 72 hours after transfection. Results 
showed that the apoptotic rate of cells trasfected with MiR-27a was about 
twice than cells transfected with MiR-negative control (Fig.22).  
 
 
Figure 22. RS4;11 cell apoptosis was assessed by annexin-V-FITC and PI staining. Early 
apoptotic cells are those marked with AXV, whereas late apoptotic cells show AXV and PI 
staining. Cytofluorimetric analysis was performed 72 h after MiR-27a transfection. Results 
are reported as cytogram (top panels) and bar graph (bottom panel). Data are shown as 
mean of three independent experiments. Error bars indicate the standard deviations.  
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In addition, to test whether MiR-27a overexpression affected clonogenic 
capacity of t(4;11) cells, we performed a colony-formation assay, using the 
semi-solid methylcellulose-based media MethoCult™. To this aim, we 
transfected pre-MiR-27a or pre-MiR-negative control in RS4;11 cells and 24 
hours after, we cultured transfected cells in the MethoCult medium. After two 
weeks in culture, we detected fewer and smaller colonies in cells transfected 
with pre-MiR-27a than in the control ones (Fig.23). 
Overall, these results indicate that MiR-27a has a tumor suppressor activity in 
t(4;11) leukemia context. 
 
 
Figure 23. Colony-formation assay, by using MethoCult™. RS4;11 cells transfected with 
MiR-27a were cultured in a semi-solid methylcellulose-based media, 24 h after transfection. 
Pictures are representative of differences in size (top panels) and number (bottom panels) of 
colonies obtained from RS4;11 transfected with pre-MiR-27a or pre-MiR-negative control, at 
day 14 (two fields for plate). Bar graph represents colony number (%) after 2 weeks in 
culture. Results represent the average of three independent experiments, which were 
analyzed by two independent observers. Error bars indicate the standard deviations. 
Statistical significance was calculated by one-way two tail paired T-test. p-value are 
indicated as follows: *=p<0.05, **=p<0.01, *** p =<0.005. 
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4.6 MiR-27a and 14-3-3θ expression level in t(4;11) leukemia patients 
 
To further analyze the role of the MiR-27a in the context of t(4;11) ALL, we 
also evaluated MiR-27a baseline levels in patients affected by t(4;11) ALL. 
Since low MiR-27a expression correlates to relapse-free survival in ALL 
patients (Han et al, 2011), we used patients affected by t(12;21) ALL as 
reference system. The t(12;21)(p13;q22) translocation, which gives rise to the 
ETV6/RUNX1 fusion gene, is an indicator of good prognosis (Alvarez Y et al, 
2005). Therefore, we collected total RNA extracted from leukemic blasts of 
patients and performed RT-qPCR with MiR-27a-specific TaqMan
TM 
probe to 
evaluate MiRNA levels. Furthermore, taking into account the crucial role of 
14-3-3θ in the t(4;11) leukemia (Fioretti et al, submitted), we also evaluated 
transcript levels of 14-3-3θ. Data showed that t(4;11) patients had lower MiR-
27a levels than t(12;21) patients (Fig.24A). In contrast, although 14-3-3θ 
transcript levels appeared to be slightly higher in t(4;11) than t(12;21) ALL 
patients, the difference was not statistically significant (Fig.24B). However, 
taking into account inter-individual expression variability and the relatively 
small number of analyzed patients, these results tend to be in line with the 
inverse correlation between expression levels of MiR-27a and 14-3-3θ we 
observed in t(4;11) leukemia cell lines and support the correlation between 
MiR-27a levels and relapse-free survival in ALL patients. 
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Figure 24. RT-qPCR to measure (A) MiR-27a and (B) 14-3-3θ transcript level in t(4;11) 
patients vs patients affected by t(12;21) ALL. MiR-27a level was normalized to the U18 gene, 
whereas 14-3-3θ level to ACTB and PolR2A genes. Relative gene expression was determined 
using Bio-Rad CFX Manager Gene Expression tool; machinery tool information: normalized 
expression mode  ΔΔCq, none control sample.  
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5. DISCUSSION  
In this study we demonstrate that MiR-27a has a crucial role in pathogenesis 
of t(4;11) ALL, because it impacts on expression and function of the main 
players of this type of leukemia. It is well known that miRNAs have 
important role in modulating hematopoietic process, by targeting genes 
involved in regulation of cell proliferation, metabolism and apoptosis 
(Organista-Nava et al, 2016). In particular, MiR-27a is downregulated in 
various acute leukemias where it functions as a tumor suppressor, through the 
targeting of 14-3-3θ (Scheibner et al, 2012). The t(4;11) ALL is caused by the 
t(4;11)(q21;q23) chromosomal translocation, which gives rise to the MLL-
AF4 oncogenic chimera. Of note, initiation and maintenance of leukemic 
phenotype depends on the aberrant expression of a set of MLL-AF4 chimera 
target genes, including HOXA9 and MEIS1 (Roth et al, 2009). Notably, 
previous data obtained in our laboratory have demonstrated that 14-3-3θ, a 
direct interactor of AF4, has a key role in the molecular pathogenesis of 
t(4;11) leukemia, because its silencing negatively affects expression of 
HOXA9 and MEIS1, induces apoptosis and hampers proliferation of t(4;11) 
leukemia cell lines, which constitutively express MLL-AF4 (Fioretti et al, 
submitted). Based on this knowledge, MiR-27a represents a good candidate to 
further study leukemia pathogenesis because it is potentially able to 
downregulate 14-3-3θ. 
In an effort to analyze the potential role of MiR-27a in t(4;11) leukemia, we 
firstly evaluated its expression level in different leukemia cell lines. We 
found that MiR-27a level was relatively low in t(4;11) ALL cells (RS4;11 and 
SEM); moreover, we observed an inverse correlation between MiR-27a and 
14-3-3θ transcript levels, which was particularly relevant in t(4;11) cell lines. 
Based on this data, we enhanced cellular level of MiR-27a by transfection and 
analyzed the resulting molecular and cellular consequences on the t(4;11) 
leukemia context. We found that 14-3-3θ protein level decreased after MiR-
27a overexpression, thereby confirming that MiR-27a targets 14-3-3θ also in 
RS4;11 leukemia cells. 
It is well known that a single miRNA targets and regulates several different 
transcripts. Thus, we looked for additional MiR-27a potential targets involved 
in leukemia pathogenesis and interestingly found several putative seed 
sequences of MiR-27a within AFF1-3’-UTR. The AFF1 gene encodes the 
AF4 protein, a key player in the molecular pathogenesis of t(4;11) ALL and a 
direct interactor of 14-3-3θ. AF4 is a nuclear transcriptional activator and a 
component of the SEC/AEP complex that is aberrantly recruited by MLL-
AF4 oncoprotein on target gene promoters (Yokoyama et al, 2010). Most 
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importantly, AFF1 shares the same 3’-UTR with the MLL-AF4 fusion gene, 
thus suggesting that transcripts encoding AF4 and MLL-AF4 are potential 
targets of MiR-27a. By luciferase reporter assay, we prove that MiR-27a 
directly binds to the AFF1 3’-UTR. Accordingly, its overexpression strongly 
reduces endogenous AF4 and MLL-AF4 protein levels in t(4;11) leukemia 
cells. Moreover, we demonstrated that MiR-27a overexpression reduces 
protein level of its known target RUNX1, also in the t(4;11) leukemia contest. 
So far, our experiments prove that MiR-27a is able to reduce expression of 
four important oncogenes in t(4;11) leukemia, namely 14-3-3θ, RUNX1, AF4 
and MLL-AF4. Taking into account these results, we tested the possibility 
that MiR-27a affected MLL-AF4 chimera functionality and interestingly 
found that MiR-27a overexpression reduced transcript level of the main 
chimera target genes, i.e. HOXA9, HOXA7 and MEIS. Notably, the up-
regulation of these genes is a hallmark of t(4;11) leukemia (Yokoyama et al, 
2010). The decreased expression of the main chimera target genes is in line 
with the reduced MLL-AF4 bound to HOXA9 gene promoters, as our ChIP 
experiment demonstrated. Notably, MiR-27a negatively impairs only the 
binding of MLL-AF4 to HOXA9pr, whereas binding of MLL wild type is not 
affected. Interestingly, this latter result seems in contrast to recent evidence 
indicating that MLL wild type and MLL-AF4 compete for binding to the 
promoter of target genes, including the HOXA genes (Liang et al, 2017). Such 
data arise from studies performed in HEK293 cells that expressed 
endogenous MLL and recombinant MLL-AF4 (stable transfectant). We 
explain our conflicting results by assuming that, as MiR-27a also targets AF4 
and 14-3-3θ, in the most pathophysiological system such as the t(4;11) cell 
lines, deficiency of AF4 and 14-3-3θ prevents MLL to restore the 
physiological transcriptional complex. 
The tumor suppressor role of MiR-27a in t(4;11) leukemia context is also 
supported by its effects on leukemia cellular phenotype. Indeed, we prove that 
MiR-27a overexpression reduces viability and proliferative capability of 
t(4;11) leukemia cells and moreover increases their apoptosis rate. The latter 
evidence is in line with literature data demonstrating that HOXA9 knockdown 
hampers the proliferative potential of t(4;11) leukemia cells (Kroon E et al, 
1998) and with the anti-apoptotic role of the 14-3-3 proteins (Cau et al, 2018). 
Loss of differentiation and gain of uncontrolled proliferation are crucial 
features of leukemic blasts. Evaluation of blasts capability to form colonies, 
and the number and the morphology of the colonies may provide preliminary 
information about the potential of progenitors to differentiate and proliferate 
(Sarma et al, 2010). In accordance, we tested the potential involvement of 
MiR-27a in the clonogenic capability of RS4;11 leukemic blasts. After two 
weeks of culture in a semi-solid medium, we detected fewer and smaller 
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colonies in MiR-27a transfected cells than in the control cells, thereby 
proving that MiR-27a interferes with clonogenic potential of the leukemic 
cells. 
Of note, MiR-27a is expressed at lower level in relapse infant and childhood 
ALL patients compared with primary patients at diagnosis, suggesting that 
leukemia relapse might be a consequence of MiR-27a de-regulation (Feng et 
al, 2011; Han et al, 2011). Since MLL-AF4 leukemia has the worst prognosis 
among the MLL-r leukemias (Winters et al, 2017), we asked whether t(4;11) 
patients have a particular expression profile of MiR-27a with respect to 
patients affected by a type of leukemia with a favourable outcome. To this 
aim, we selected ALL patients with t(12;21) translocation, since it is an 
indicator of benign prognosis (Alvarez et al, 2005). Very interestingly, we 
found that t(4;11) patients had lower levels of MiR-27a than t(12;21) patients; 
on the contrary, 14-3-3θ transcript levels tended to be slightly higher in 
t(4;11) than in t(12;21) patients, considering however inter-individual 
expression variability. 
Overall, our results prove the concept that enhancing expression levels of 
MiR-27a could be a new strategy to improve clinical outcome of patients 
affected by the aggressive t(4;11) ALL. 
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6. CONCLUSIONS 
This study aimed to define the role of MiR-27a in the pathogenesis of the 
t(4;11) acute lymphoblastic leukemia. Here, we provide an experimental 
correlation between literature data reporting that MiR-27a expression level 
correlates with relapse-free survival of ALL patients and the poorest 
prognosis associated to the t(4;11) ALL. The low MiR-27a expression levels 
found in t(4;11) patients indicate that pathogenic mechanism causing 
leukemia needs downregulation of MiR-27a to escape the underlying fine 
regulation that controls availability of key molecules with oncogenic activity, 
including MLL-AF4, AF4, RUNX1 and14-3-3θ. Unveiling molecular 
mechanism associated to MiR-27a de-regulation could be useful to test an 
alternative strategy to enhance MiR-27a cellular level.  
In conclusion, here we define MiR-27a as a tumor suppressor in the t(4;11) 
leukemia and prove that modulation of its endogenous expression might be a 
promising therapeutic options for this untreatable and very aggressive type of 
leukemia. 
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7. APPENDICES 
APPENDIX A 
 
 
Appendix A. (A) TargetScan, (B) MicroRNA.org, (C) Diana tools output. Each 
bioinformatics result highlights the alignment of putative seed sequences of MiR-27a with 
AFF1 3’-UTR, the position of the putative seed sequence and the score calculated by each 
database prediction algorithm. 
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APPENDIX B 
 
 
Appendix B. Luciferase reporter assay to measure Renilla activity, after MiR-27a 
transfection in RS4;11 cells. To perform experiment, three different psiCHECK-2 constructs 
were used, which contain 1-AFF1-3’-UTR or 2-AFF1-3’-UTR or 3-AFF1-3’-UTR 
overlapping fragments, respectively, and overall cover the entire AFF1-3’-UTR. 
Normalization was performed to firefly Luciferase activity. The shown results are the mean 
from three independent experiments. Error bars indicate standard deviations. Statistical 
significance was calculated by one-way two tail paired T-test. p‐ value are indicated as 
follows: **=p<0.01, *** p =<0.005. 
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APPENDIX C 
 
Appendix C. RT-qPCR to monitor the expression level of the MiR-27a 18-24-36h after 
transfection in (A) SEM and (B) MV;11 cell lines. Measures are normalized to the U18 
endogenous control gene. Relative gene expression was determined using the 2
-ΔΔCt
  method. 
Results are the mean values from three independent experiments. Error bars indicate 
standard deviations. Statistical significance was calculated by one-way two tail paired T-test. 
p‐ value are indicated as follows: *=p<0.05; **=p<0.01. 
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